source
- Epkinly shows 51% PFS boost in frontline DLBCL, may become new standard of careAbbVie and Genmab reported that their bispecific antibody Epkinly achieved a substantial gain in progression‑free survival when added to the standard R‑CHOP regimen in newly diagnosed diffuse large…
- AstraZeneca launches $1 billion R&D hub in Boston’s Kendall SquareAstraZeneca opened a new research and development site in Kendall Square, Boston, marking a $1 billion investment in the U.S. biotech corridor. The Boston location underscores the company’s commit…